Gedeptin is a Gene Therapy owned by GeoVax Labs, and is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing.

Gedeptin, Ad/PNP containing the E. coli PNP gene is injected into the tumor where it infects the tumor cell and produces the E. coli PNP enzyme. Upon administration, fludarabine phosphate is dephosphorylated to 2-fluoro-ara-A by plasma enzymes. F-araA diffuses into the tumor cell where it is converted to 2-fluoroadenine by the E. coli PNP enzyme and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. It kills the tumor cell in which it was originally made and also destroys neighboring tumor cells not infected with the vector.

The revenue for Gedeptin is expected to reach a total of $37m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Gedeptin NPV Report.

Gedeptin was originated by Southern Research Institute and UAB Minority Health and Health Equity Research Center and is currently owned by GeoVax Labs.

Gedeptin Overview

Gedeptin (Ad/PNP-F-araAMP) is under development for the treatment of oropharyngeal cancer and head and neck cancer. Ad/PNP is administered intratumorally with co-administration of fludarabine phosphate intravenously. Adenovirus/PNP is an adenovirus loaded with E. coli purine nucleoside phosphorylase (E. coli PNP). The drug candidate is developed based on PNP Technology.

GeoVax Labs Overview

GeoVax Labs (GeoVax) is a biotechnology company that develops immunotherapies and vaccines against cancers and various infectious diseases. GeoVax develops vaccines using its novel patented Modified Vaccinia Ankara-Virus like Particle (MVA-VLP) vector vaccine platform focused on therapy areas such as infectious diseases like HIV, Lassa fever, Ebola, Zika virus, malaria, Hepatitis B, coronavirus, and cancers related to solid tumors and HPV-associated head and neck cancer. The company has partnerships for preclinical and clinical testing with various government, academic and corporate entities, including the Centers for Disease Control and Prevention (CDC), Leidos Inc, Scripps Research Institute, and Emory University. GeoVax is headquartered in Smyrna, Georgia, the US.

The company reported revenues of (US Dollars) US$0.4 million for the fiscal year ended December 2021 (FY2021), a decrease of 78.8% over FY2020. The operating loss of the company was US$18.6 million in FY2021, compared to an operating loss of US$2.8 million in FY2020. The net loss of the company was US$18.6 million in FY2021, compared to a net loss of US$3 million in FY2020.

Quick View – Gedeptin

Report Segments
  • Innovator
Drug Name
  • Gedeptin
Administration Pathway
  • Intratumor
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.